BCG vaccine effectiveness in preventing tuberculosis and its interaction with human immunodeficiency virus infection

dc.creatorArbeláez Montoya, María Patricia
dc.creatorNelson, Kenrad E.
dc.creatorMuñoz, Álvaro
dc.date2023-03-14T01:00:04Z
dc.date2023-03-14T01:00:04Z
dc.date2000
dc.date.accessioned2024-04-23T14:10:30Z
dc.date.available2024-04-23T14:10:30Z
dc.identifierArbeláez MP, Nelson KE, Muñoz A. BCG vaccine effectiveness in preventing tuberculosis and its interaction with human immunodeficiency virus infection. Int J Epidemiol. 2000 Dec;29(6):1085-91. doi: 10.1093/ije/29.6.1085.
dc.identifier0300-5771
dc.identifierhttps://hdl.handle.net/10495/33975
dc.identifier10.1093/ije/29.6.1085
dc.identifier1464-3685
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/9229182
dc.descriptionABSTRACT: Background: To explore Bacillus Calmette-Guérin vaccine (BCG) as a protective factor against tuberculosis (TB) and how human immunodeficiency virus (HIV) infection modifies the effect of BCG on TB. Methods: Two matched case-control studies were conducted. One study compared TB cases and controls who were HIV positive. The second compared TB cases and controls who were HIV negative. The study population consisted of 88 TB cases and 88 controls among HIV-positive individuals and 314 TB cases and 310 controls among HIV-negative individuals. Cases were new TB diagnoses, confirmed by either bacteriology, pathology, radiology or clinical response to treatment; controls were selected from people without TB symptoms and who sought medical attention in the same institution where a case was enrolled. BCG was assessed by the presence of a typical scar. Results: The level of protection against all clinical forms of TB was 22% among HIV positive individuals (odds ratio [OR] = 0.78, 95% CI : 0.48-1.26) and 26% among HIV negatives (OR = 0.74, 95% CI : 0.52-1.05). There was a significant difference (P = 0.002) in the level of protection against extrapulmonary TB (ETB) between HIV-negative (OR = 0.54, 95% CI : 0.32-0.93) and HIV-positive individuals (OR = 1.36, 95% CI : 0.72-2.57). Conclusion: BCG has a modest protective effect against all forms of TB independent of HIV status, and BCG confers protection against extrapulmonary TB among HIV-negative individuals. However, HIV infection seems to abrogate the protective effect of BCG against extrapulmonary TB. Our data support the public health importance of BCG vaccine in the prevention of extrapulmonary TB among immunocompetent individuals.
dc.descriptionCOL0014789
dc.descriptionCOL0004362
dc.format7
dc.formataplicatión/pdf
dc.formatapplication/pdf
dc.languageeng
dc.publisherInternational Epidemiological Association
dc.publisherPolíticas Sociales y Servicios de Salud
dc.publisherEpidemiología
dc.publisherLondres, Inglaterra
dc.relationInt. J. Epidemiol.
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightshttp://creativecommons.org/licenses/by-sa/2.5/co/
dc.rightshttp://purl.org/coar/access_right/c_abf2
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/4.0/
dc.subjectTuberculosis
dc.subjectVacuna BCG
dc.subjectBCG Vaccine
dc.subjectInfecciones por VIH
dc.subjectHIV Infections
dc.subjectEstudios de Casos y Controles
dc.subjectCase-Control Studies
dc.subjectColombia - epidemiología
dc.subjectColombia - epidemiology
dc.subjectEnsayo de Inmunoadsorción Enzimática
dc.subjectEnzyme-Linked Immunosorbent Assay
dc.subjectComorbilidad
dc.subjectComorbidity
dc.subjectResultado del Tratamiento
dc.subjectTreatment Outcome
dc.titleBCG vaccine effectiveness in preventing tuberculosis and its interaction with human immunodeficiency virus infection
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typehttp://purl.org/coar/resource_type/c_2df8fbb1
dc.typehttps://purl.org/redcol/resource_type/ART
dc.typeArtículo de investigación


Este ítem pertenece a la siguiente institución